Lucid Diagnostics (LUCD) Cash from Investing Activities Growth (1y) (2022 - 2026)
Lucid Diagnostics (LUCD) Cash from Investing Activities Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -15.64% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | -514.42% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | -87.14% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -73.71% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -12.26% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 618.55% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 48.43% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 91.33% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 0.00% |
| 10 | Lucid Diagnostics | 175.80 Mn | 142.40 Mn | 55,000.00 | 16.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.00% |
| Mar 31, 2026 | -131.18% |
| Dec 31, 2025 | 80.31% |
| Sep 30, 2025 | 92.00% |
| Mar 31, 2025 | -151.35% |
| Dec 31, 2024 | -48.00% |
| Sep 30, 2024 | -2,400.00% |
| Mar 31, 2024 | -117.65% |
| Dec 31, 2023 | 13.79% |
| Sep 30, 2023 | 98.94% |
| Jun 30, 2023 | 99.38% |
| Mar 31, 2023 | 88.51% |
| Dec 31, 2022 | 75.36% |
| Sep 30, 2022 | -4,617.86% |
| Jun 30, 2022 | -243,500.00% |
| Mar 31, 2022 | -1,544.44% |